Publications - Eir Biotherapies

Tonelli R, Pischiutta F, Elice F, Zanier ER, Grisendi G, Astori G, Samarelli AV, Bruzzi G, Manicardi L, Spano C, Nattino G, Signorini F, Bernardi M, Catanzaro D, Merlo A, Lisi I, Pasetto L, Bonetto V, Fiammenghi L, Boschi L, Guidi S, Candini O, Zoerle T, Dander E, D'Amico G, De Pierri F, Maur M, Pettorelli E, Ruggieri V, Cerri S, Mari G, De Berardis G, Mighali P, Baschieri MC, Lazzari L, Bambi F, Ciccocioppo R, Clini E, Dominici M; RESCAT study group. Impact of mesenchymal stromal/stem cell infusions on circulating inflammatory biomarkers in COVID-19 patients: analysis of a phase I-IIa trial. Cytotherapy. 2025 Apr 7:S1465-3249(25)00677-2. doi: 10.1016/j.jcyt.2025.04.059.

Grisendi G, Dall'Ora M, Casari G, Spattini G, Farshchian M, Melandri A, Masciale V, Lepore F, Banchelli F, Costantini RC, D'Esposito A, Chiavelli C, Spano C, Spallanzani A, Petrachi T, Veronesi E, Ferracin M, Roncarati R, Vinet J, Magistri P, Catellani B, Candini O, Marra C, Eccher A, Bonetti LR, Horwtiz EM, Di Benedetto F, Dominici M. Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma. Cell Rep Med. 2024 Aug 20;5(8):101685. doi: 10.1016/j.xcrm.2024.101685.

L’oncologo Dominici (Università di Modena e Reggio): una sinergia di terapia cellulare-genica e chemio si è dimostrata efficace in vitro e nei topi, riducendo la massa del cancro e le metastasi.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7.

Müller I, Kordowich S, Holzwarth C, Spano C, Isensee G, Staiber A, Viebahn S, Gieseke F, Langer H, Gawaz MP, Horwitz EM, Conte P, Handgretinger R, Dominici M. Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy. 2006;8(5):437-44.

Horwitz EM, Dominici M. How do mesenchymal stromal cells exert their therapeutic benefit? Cytotherapy. 2008;10(8):771-4. doi: 10.1080/14653240802618085.

Dominici M, Paolucci P, Conte P, Horwitz EM. Heterogeneity of multipotent mesenchymal stromal cells: from stromal cells to stem cells and vice versa. Transplantation. 2009 May 15;87(9 Suppl):S36-42. doi: 10.1097/TP.0b013e3181a283ee.

Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, De Santis G, Spano C, Tagliazzucchi M, Barti-Juhasz H, Scarabelli L, Bambi F, Frassoldati A, Rossi G, Casali C, Morandi U, Horwitz EM, Paolucci P, Conte P, Dominici M. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 2010 May 1;70(9):3718-29. doi: 10.1158/0008-5472.CAN-09-1865.

Grisendi G, Annerén C, Cafarelli L, Sternieri R, Veronesi E, Cervo GL, Luminari S, Maur M, Frassoldati A, Palazzi G, Otsuru S, Bambi F, Paolucci P, Pierfranco C, Horwitz E, Dominici M. GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. Cytotherapy. 2010 Jul;12(4):466-77. doi: 10.3109/14653241003649510.

Grisendi G, Bussolari R, Veronesi E, Piccinno S, Burns JS, De Santis G, Loschi P, Pignatti M, Di Benedetto F, Ballarin R, Di Gregorio C, Guarneri V, Piccinini L, Horwitz EM, Paolucci P, Conte P, Dominici M. Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. Am J Cancer Res. 2011;1(6):787-805.